A. Surcinelli

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
A Surcinelli, Andrea Surcinelli
Publication record
28 papers · 76 citations · H-index 5

PAPERS

Effect of late-onset on multiple sclerosis phenotype and outcome: evidence from a multi-national registry
20260 citationsauthor #49
Ofatumumab Versus Intravenous Ocrelizumab after Sphingosine-1-Phosphate Receptor Modulators in Patients with Relapsing-Remitting Multiple Sclerosis: A Real-World Inverse Probability of Treatment Weighting Multicenter Study.
20260 citationsauthor #33
Impact of Age at Onset on Relapse and Disability in AQP4-IgG Neuromyelitis Optica Spectrum Disorder.
20260 citationsauthor #29
Abuse in individuals with multiple sclerosis: the SocialMS Italian study.
20260 citationsauthor #19
First-year treatment response predicts the following 5-year disease course in patients with relapsing-remitting multiple sclerosis
20255 citationsauthor #25
Real-world effectiveness of horizontal switching between disease-modifying therapies in multiple sclerosis: a retrospective analysis of the MSBase Registry
20250 citationsauthor #18
Persistent progression independent of relapse activity in multiple sclerosis
20251 citationsauthor #33
Identifying Cladribine prescription pattern in MS: an Italian multicentre study
20251 citationsauthor #8
Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple Sclerosis.
202520 citationsauthor #31
247 Clinically silent MRI lesions in RRMS: prognostic impact and an emulated trial of disease modifying therapy escalation
20250 citationsauthor #12
Four years on: Pregnancy and birth outcomes reported in the MSBase pregnancy, neonatal outcomes, and Women’s Health Registry (2020–2024)
20250 citationsauthor #29
Haematopoietic stem cell transplant versus immune-reconstitution therapy in relapsing multiple sclerosis.
20251 citationsauthor #36
Moderate–high efficacy disease-modifying therapies reduce relapse risk in late-onset multiple sclerosis
20251 citationsauthor #14
Pregnancy-Related Disease Outcomes in Women With Moderate to Severe Multiple Sclerosis Disability
20250 citationsauthor #23
Sex differences in relapse-independent and relapse-associated disability progression in relapsing-remitting multiple sclerosis: a real-world inverse-probability weighted study
20250 citationsauthor #14
Harmonized magnetic resonance imaging protocols for multiple sclerosis: HARMONY-MS, a pilot project
20250 citationsauthor #1
YI6 MS outcomes in breast cancer survivors and the influence of chemotherapy
20250 citationsauthor #13
Corticosteroid treatment of multiple sclerosis relapses is associated with lower disability worsening over 5 years
20250 citationsauthor #23
Hypogammaglobulinemia and severe infections in Multiple Sclerosis patients on anti-CD20 agents: A multicentre study.
20248 citationsauthor #7
NEDA-3 achievement in early highly active relapsing remitting multiple sclerosis patients treated with Ocrelizumab or Natalizumab.
202410 citationsauthor #23
Effectiveness of Disease-Modifying Treatment on Spinal Cord Lesion Formation in Relapse-Onset Multiple Sclerosis: An MSBase Registry Study
20240 citationsauthor #7
Predictors of relapse risk and treatment response in AQP4-IgG positive and seronegative NMOSD: A multicentre study
202410 citationsauthor #20
A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemic
20248 citationsauthor #32
Routine CSF parameters as predictors of disease course in multiple sclerosis: an MSBase cohort study
20245 citationsauthor #12
ECTRIMS 2024 – Late Breaking ePoster
20242 citationsauthor #119
3018 A multi-centre longitudinal study analysing disease modifying therapy prescribing patterns during the COVID-19 pandemic
20240 citationsauthor #14
The impact of COVID-19 infection on multiple sclerosis disease course across 12 countries: a propensity-score-matched cohort study
20245 citationsauthor #17
MSMilan2023 – Late Breaking Oral Presentations
20230 citationsauthor #31
MSMilan2023 – LB Paper Posters – Session 1
20232 citationsauthor #213

TIMELINE

2023 2 citations

2024 48 citations

2025 29 citations

2026 0 citations

A. Surcinelli

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT